FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC By Ogkologos - October 16, 2025 262 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR How My Cancer Diagnosis Has Fueled My Work in Improving Access... December 19, 2023 Could Bacteria Help Find Cancer? September 20, 2023 Sparing the Hippocampus During PCI Better Preserves Cognitive Function in Patients... August 19, 2021 Zooming in: Fine-tuning the picture to diagnose oesophageal cancer earlier August 10, 2021 Load more HOT NEWS FDA Approves Cabozantinib for Differentiated Thyroid Cancer Teacher on Leave for Breast Cancer Treatment Forced to Pay for... Breast Cancer Survivor’s Family Designs a Holiday Light Show in Her... 2-Year-Old Cancer Survivor With Down Syndrome Hears For First Time: ‘Her...
